Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing
Open accessThe DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is an endocrine-gynecology disorder affecting many women of childbearing age. Although a part of the involved mechanism in PCOS occurrence is discovered, the exact etiology and pathophysiology are not comprehensively understood yet. We searched PubMed for PCOS pathogenesis and management in this article and ClinicalTrials.gov for information on repurposed medications. All responsible factors behind PCOS were thoroughly evaluated. Furthermore, the complete information on PCOS commonly prescribed and repurposed medications is summarized through tables. Epigenetics, environmental toxicants, stress, diet as external factors, insulin resistance, hyperandrogenism, inflammation, oxidative stress, and obesity as internal factors were investigated. Lifestyle modifications and complementary and alternative medicines are preferred first-line therapy in many cases. Medications, including 3-hydroxy-3-methyl-3-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors, thiazolidinediones, sodium-glucose cotransporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors, glucose-like peptide-1 receptor agonists, mucolytic agents, and some supplements have supporting data for being repurposed in PCOS. Since there are few completed clinical trials with a low population and mostly without results on PCOS repurposed medications, it would be helpful to do further research and run well-designed clinical trials on this subject. Moreover, understanding more about PCOS would be beneficial to find new medications implying the effect via the novel discovered routes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hyperandrogenism, hyperinsulinism and insulin resistance (IR) are the main drivers of clinical, metabolic and reproductive phenotypes of PCOS.”
From Low-Calorie Ketogenic Diet: Potential Application in the Treatment of Polycystic Ovary Syndrome in Adolescents (2023) · cites this paper as [3]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Similarly, the DAI has been developed as a more specific measure of adipose tissue dysfunction by combining WC, BMI, TG levels, and HDL-C [9,10,11].”
From Visceral and Dysfunctional Adiposity Indices as Predictors of Insulin Resistance and Metabolic Syndrome in Women with Polycystic Ovary Syndrome: A Cross-Sectional Study (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The VAI is an established marker of abdominal obesity and IR, integrating WC, triglyceride (TG) levels, and high-density lipoprotein cholesterol (HDL-C) to predict metabolic risk.”
From Visceral and Dysfunctional Adiposity Indices as Predictors of Insulin Resistance and Metabolic Syndrome in Women with Polycystic Ovary Syndrome: A Cross-Sectional Study (2025) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment
Escobar-Morreale, H. F. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.24 · Cited by 2,083 · cited 3×
“In addition, it should be mentioned that studies on PCOS women approved the resemblance of their fatty tissue to men, and hence the effect of HA on adipose tissue dysfunction [8].”
BackgroundInfluentialRosenfield, R. L., & Ehrmann, D. A. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1104 · Cited by 1,603 · cited 9×
“Hyperinsulinemia increases LH-binding sites and androgen-producing response to LH [44].”
BackgroundInfluentialChronic Low Grade Inflammation in Pathogenesis of PCOS
Rudnicka, E., Suchta, K., Grymowicz, M., Calik-Ksepka, A., Smolarczyk, K., Duszewska, A. M., Smolarczyk, R., & Meczekalski, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073789 · Cited by 680
Witchel, S. F., Oberfield, S. E., & Peña, A. S. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00078 · Cited by 653
Sanchez-Garrido, M. A., & Tena-Sempere, M. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.01.001 · Cited by 557 · cited 1×
“One way androgen results in oxidative stress is by increasing MNC sensitivity to glucose and aggravating glucosestimulated oxidative stress [65].”
BackgroundPolycystic Ovarian Syndrome: Correlation Between Hyperandrogenism, Insulin Resistance and Obesity.
Zeng, X., Xie, Y.-J., Liu, Y.-T., Long, S.-L., & Mo, Z.-C. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.11.003 · Cited by 525 · cited 9×
“It also plays a role in progesterone and estrogen production, ovulation, and decreased GnRH secretion [52].”
BackgroundInfluentialA novel and compact review on the role of oxidative stress in female reproduction
Lu, J., Wang, Z., Cao, J., Chen, Y., & Dong, Y. (2018) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-018-0391-5 · Cited by 481 · cited 11×
“Taking SFAs induces inflammation by triggering an increase in TNF-α level in circulation and expressing a specific cytokine suppressor [36].”
BackgroundInfluentialIbáñez, L., Oberfield, S. E., Witchel, S., Auchus, R. J., Chang, R. J., Codner, E., Dabadghao, P., Darendeliler, F., Elbarbary, N. S., Gambineri, A., et al. (2017) · Hormone Research in Paediatrics · doi:10.1159/000479371 · Cited by 463 · cited 7×
“This receptor hypomethylation leads to higher gene expression and sensitivity to LH [18,20].”
BackgroundInfluentialCharacteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics
Glueck, C. J., & Goldenberg, N. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.002 · Cited by 442 · cited 3×
“Excess abdominal fat is also responsible for the inflammatory condition [6,44,81].”
BackgroundCassar, S., Misso, M. L., Hopkins, W. G., Shaw, C. S., Teede, H. J., & Stepto, N. K. (2016) · Human Reproduction · doi:10.1093/humrep/dew243 · Cited by 415 · cited 1×
“On the other hand, hyperinsulinemia reduces hepatic SHBG [18,32,40,49,52,54–56], increasing free testosterone levels in blood [18,32,52,54,56].”
Background
Research works printed but not linked: 3
- Casadesús J. Noyer-Weidner M. Epigenetics Brenner’s Encyclopedia of Genetics 2nd ed. Maloy S. Hughes K. Academic Press San Diego, CA, USA 2013 500 503
- Jones L. Regan F. Endocrine Disrupting Chemicals Encyclopedia of Analytical Science 3rd ed. Worsfold P. Poole C. Townshend A. Miró M. Academic Press Oxford, UK 2019 31 38
- Zeind C.S. Carvalho M.G. Applied Therapeutics: The Clinical Use of Drugs Wolters Kluwer Health Philadelphia, PA, USA 2017
Cited by
Items 401–497 of 497
Zhulikova, M. V., Myroshnychenko, M. S., Zhulikova, O. O., Kapustnyk, N. V., Hromko, Y. A., & Myroshnychenko, S. O. (2025) · Wiadomości Lekarskie · doi:10.36740/wlek/209557
“Polycystic ovary syndrome (PCOS) is one of the most prevalent hormonal and metabolic disorders, affecting 8-13% of women of reproductive age and 3-11% of adolescent girls [1, 2].”
Feng, Y., Chen, Y., & Feng, Q. (2025) · Research Square · doi:10.21203/rs.3.rs-7509311/v1
Qiu, M., Qu, J., Wang, J., Zhi, Y., & Teng, X. (2025) · Reproductive Sciences · doi:10.1007/s43032-025-01994-5 · Cited by 1
Duarte, L. M., & Navarro, A. M. (2024) · doi:10.11606/003244614
Yang, L., Gao, Y., Zhao, W., Qi, Y., Duo, X., & Wang, H. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1683556 · Cited by 1
Wang, H., Chen, Y., Wang, Q., Xu, S., & Wu, X. (2025) · Endocrine Connections · doi:10.1530/ec-25-0608
Assessment of Body Image Disturbance in Women with Polycystic Ovary Syndrome
Debo, M. Y., Issa, M. A., & Haddad, A. M. (2025) · Nursing and Health · doi:10.13189/nh.2025.100201
Research Progress on Tumor Necrosis Factor-α and Ovarian Diseases
潘, 慧. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15103026
Li, Y., Li, L., Zheng, H., Zhong, L., Li, W., Ding, L., Zhang, M., He, Z., & Luo, X. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01811-2 · Cited by 2
“Despite its significant prevalence and health impact, the precise etiopathogenesis of PCOS remains incompletely understood, involving a complex interplay between genetic predisposition, epigenetic modifications, and environmental factors [4].”
Hasman, M. V. F., Raimundo, L. A., & Villela, A. D. O. R. (2025) · Contribuciones a las Ciencias Sociales · doi:10.55905/revconv.18n.10-304
Vargas, R. M. A. R., Ayón-Aguilar, J., López, P. V. F., & Ku, A. J. M. (2025) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v9i5.20468
Tariq, Z., Javed, A., Amir, F., Liaquat, A., Tahir, M., Khizar, W., & Khan, M. J. (2025) · Middle East Fertility Society Journal · doi:10.1186/s43043-025-00274-1
Prediabetes is a window of opportunity for preventive interventions. Part 1
Adasheva, T. V., Евгеньевна, Г. Е., Игоревна, Ф. Е., & Георгиевна, Л. Е. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-407
Wang, Y., Liu, J., Jiang, Y., Liu, Y., Kuang, H., & Feng, X. (2025) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-025-01124-0
“Emerging evidence positions chronic inflammation and oxidative stress as pivotal contributors to GC dysfunction (Duleba and Dokras, 2012; Snider and Wood, 2019; Sadeghi, et al .”
Ulloque‐Badaracco, J. R., Hernández-Bustamante, E. A., Cabrera-Guzmán, J. C., Delgado-Raygada, J. E., Dotto-Vasquez, G., Maldonado-Basurto, G. F., Figueroa-Larragán, A. A., Trujillo-Jurado, K. Z., Ballmann, G. E., Flores-Gavino, A., et al. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251397203 · Cited by 3
“12,88 In this context, LAP and VAI are valuable indicators to discriminate insulin resistance in patients with PCOS.”
InfluentialKwon, H.-R., Shim, S. B., Yun, S.-Y., Choi, E.-Y., Kim, M.-K., Lee, H. L., & Kim, S.-B. (2025) · 대한한의학회지 · doi:10.13048/jkm.25057
Jamwal, S., Soni, A., Dhaiya, D. P., & Kumar, A. (2024) · African Journal of Biomedical Research · doi:10.53555/ajbr.v27i1.8829
Ji, D., Gu, H., & Wang, H. (2025) · International Journal of Women s Health · doi:10.2147/ijwh.s557855
Zou, L., Li, W., Xu, D., Zhu, S., & Jiang, B. (2023) · Figshare · doi:10.6084/m9.figshare.23902857
Harzif, A. K., Pratamasari, S. M. R., Rumapea, C. T. P., Ummah, N., Mutia, H., Nurbaeti, P., Puspawardani, A. R., & Wiweko, B. (2024) · Figshare · doi:10.6084/m9.figshare.26753137
Harzif, A. K., Pratamasari, S. M. R., Rumapea, C. T. P., Ummah, N., Mutia, H., Nurbaeti, P., Puspawardani, A. R., & Wiweko, B. (2024) · Figshare · doi:10.6084/m9.figshare.26753134
Zou, L., Li, W., Xu, D., Zhu, S., & Jiang, B. (2023) · Figshare · doi:10.6084/m9.figshare.23902860
Mohamed, R. A., Taref, N. N., Osman, N. E., Keshta, N. H. A., Alboghdady, M. A., Marzouk, M. M., Almowafy, A. A., & Fadel, E. A. (2024) · Figshare · doi:10.6084/m9.figshare.26749307
MEDIKAMENTINIS POLICISTINIŲ KIAUŠIDŽIŲ SINDROMO GYDYMAS
Liškauskaitė, R., & Žukienė, G. (2025) · Health Sciences · doi:10.35988/sm-hs.2025.329
Revisiting polycystic ovarian syndrome: Recent updates in diagnosis and management strategies
Al-Yasari, D. E. K. H., Alkafaji, D. S. M. A., & Abass, H. M. (2025) · Perinatal Journal · doi:10.57239/prn.25.03320035
Mir, B., Bashir, S., Shah, I., Geer, M. I., & Ganie, M. A. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898810962125010011
MicroRNA Crossroads in PCOS and Endometriosis
Sambath, G., Kalai, J., Usha Rani, G., Osborne, J. W., Sumitha, R., & Parvathi, V. D. (2025) · Reproductive Sciences · doi:10.1007/s43032-025-02037-9
“Because endometriosis can negatively impact the ovary, the oocyte, and the endometrium predominantly owing to persistent and systemic inflamma - tion, the condition is closely linked to infertility [38, 39] Its prevalence is notably high in women between the age group of 25–35 [40].”
Guan, L., Wu, H., Li, Y. Q., Yu, Y., Xiang, S., & Lian, F. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01934-6
“Polycystic ovary syndrome (PCOS), a prevalent reproductive endocrine disorder, can affect about 10% of women of child-bearing age [1].”
Pogoda, M., Pietrzyk, D., Furtak, G., Łagódka, M., Zając, K., Oder, B., Daniszewski, W., Knobelsdorf, W., Karchut, W., & Gałuszka, B. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4174
Sahib, F. J., Hassan, M. S., & Al-Sabbagh, J. K. (2025) · Kerbala Journal of Veterinary Medical Sciences · doi:10.65639/kjvm.25.031
“Importantly, PCOS is related with significant long-term health consequences, including increased risks of cardiovascular disease, diabetic-type 2, metabolic disorders, and psychiatric comorbidities such as anxiety and depression (2).”
Klinikte Endometriozis ve Polikistik Over Sendromu Yönetimi
Adalı, A., Yıldırım, F., & Duman, N. B. (2025) · Hitit sağlık dergisi. · doi:10.69563/hititsaglikderg.1726835
Zhuang, Z., Sun, F., Fan, B., Wu, H., Luo, C. L., & Ren, Q. (2026) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.119623
Dietary prevention and diet therapy for selected reproductive healthdisorders in women
Szymkowiak, A., & Pisarski, R. K. (2025) · Zeszyty Naukowe Collegium Witelona · doi:10.5604/01.3001.0055.5686
Medicinal and Nutritional Importance of Nardostachys jatamansi in Human Health
Ganguly, S., Sinha, D., Bhattacharya, R., Patel, D., Salik, A., Mukhopadhyay, S., Saldanha, P. K., Kar, S., Kumari, S., & Ansari, M. A. (2026) · Springer eBooks · doi:10.1007/978-981-95-3620-7_23
Kosęda, J., Łagowski, R., Juniewicz, H., Kudlińska, Z., Heryć, P., Kananowicz, K., Laska, Z., Latour, M., Jędrasiak, A., & Piotrowski, J. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4354
Role of sclerostin in the bone and thyroid metabolism in patients with ovarian polycystic syndrome
Al-Joubouri, Z. T., Shamran, S. G., Aziz, M. L., & Al-Fahham, A. A. (2025) · Polski Merkuriusz Lekarski · doi:10.36740/merkur202506109
Dutta, S., & Mitra, P. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100223
Arisha, R., Sengupta, S., Dewangan, H. K., Saeedan, A. S., Ansari, M. N., & Rashid, S. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156397
Khan, D. A., Jabin, A., Jilani, S., Azam, R., & Anees, S. (2026) · Hippocratic Journal of Unani Medicine · doi:10.4103/hjum.hjum_140_25
Identification of Important Risk Factors for Hypoproteinemia in Polycystic Ovaries Patients
Cheng, Z., & Lu, Y. (2026) · International Journal of Women s Health · doi:10.2147/ijwh.s577943
An Enhanced PCOS-MLPro Diagnosis Model Using Multi-Dimensional Clinical Indicators
Shalini, M., Josika, M., Geerthigaa, G., Abiraina, K., & Gomathi, S. (2026) · International Conference on Mobile Computing and Sustainable Informatics (ICMCSI) · doi:10.1109/icmcsi67283.2026.11412545
“In their work on aetiology and molecular signature, the machine learning literature was guided by prior biological analysis in [12], while an elaborate diagnostic model in [11] acted as one of the early motivations for full end-to-end PCOS prediction tools.”
Álvarez, J. P. G., Murcia, D. M. G., Reina, H. S. L., Isaac, N. G., & Torres-Pradilla, M. (2026) · Piel · doi:10.1016/j.piel.2025.12.012
Mohammed, I. F., Abdullah, T. H., Mossa, H. A. L., & Al‐Obaidi, M. T. (2026) · Journal of Obstetrics Gynecology and Cancer Research · doi:10.24200/jogcr.11.4.305
孟, 黎. (2026) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2026.52111
N., M., .VIGNES, M., & M., P. (2026) · International Journal of Science Strategic Management and Technology · doi:10.55041/ijsmt.v2i4.159
Research Progress on the Mechanism of Androgen Hyperplasia in Polycystic Ovary Syndrome
张, 馨. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641497
POLYCYSTIC OVARY SYNDROME: DIAGNOSTIC CRITERIA AND TREATMENT METHODS
Володимирівна, П. С., & Zelenska, D. (2026) · Middle European Scientific Bulletin · doi:10.65237/2336-3630-2026-4(2)-10
AMARAL, N. F., ANGELINO, G. M., BATISTA, A. M., MATOS, L. S. D., SILVA, S. R. D., NASCIMENTO, D. D. G. D., Evaristo, G. M., FURTADO, T. D. O., CORRÊA, D. D. O., de Assunção, T. C. A., et al. (2026) · Editora Pasteur eBooks · doi:10.59290/4002032051
Daniel, B. B., de Abreu, G. V. D. C., Silva, T. C. V. E., Morais, S. D., PEREIRA, L. B., da Silva, C. K. M., Giorgetti, J. M., Marques, C. A., Bernardes, C. F., Resende, A. F. P., et al. (2026) · Editora Pasteur eBooks · doi:10.59290/978-65-6029-359-5
Sapna, I. S., Patil, G. L., Pooja, H., & Desai, V. M. (2026) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20261261
Dietary Herbs as Nutraceuticals: Applications to Treating Polycystic Ovary Syndrome
Awasthi, S., Tengli, A., Gupta, D., Wal, A., & Parida, G. R. (2025) · Springer eBooks · doi:10.1007/978-3-031-32047-7_29-1
A review of the role of physical activities in managing polycystic ovary syndrome symptoms
Orofino, F., Allibrio, E., Paternò, V., Crescimanno, C., & Pallotti, F. (2026) · Sport Sciences for Health · doi:10.1007/s11332-026-01757-y
The Effectiveness of Ayurvedic Treatment Strategies on Primary Infertility: A Case Report
Narwade, P., & Swathi, C. (2026) · Journal of Ayurveda and Integrated Medical Sciences · doi:10.21760/jaims.11.4.73
VAGINAL MICROBIOME ALTERATIONS IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME
Makulec, G., Zienkiewicz, D., Domosud, K., Kostro, J. M., Novik, L., Kozicki, M. J., Libera, A., Bartkiewicz, K., & Jędra, Z. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5079
PCOS Diagnosis: Comparison of Centralized and Federated Learning
Tekrour, A., & Hadi, M. Y. (2026) · Lecture notes in networks and systems · doi:10.1007/978-3-032-22567-2_17
刘爱芬, Hu, J., Yu, W., Cang, C., Shi, C., Wang, X. R., Wang, R., 蔡宣卫, Zhao, F., & Zhang, L. (2026) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2026.05.011
THBS1: a biomarker for PCOS and its role in pathogenesis via the PI3K/AKT signaling pathway
Zhang, J., Jin, L., Chi, C., Hou, W., & Hou, W. (2026) · Mammalian Genome · doi:10.1007/s00335-026-10237-0 · Cited by 1
“Roughly 10% of women are predicted to experience PCOS prior to menopause and deal with its implications (Sadeghi et al. 2022 ).”
Mahapatra, A., Pillai, G., Rana, R., Shah, Z., & Nampoothiri, L. P. (2026) · Scientific Reports · doi:10.1038/s41598-026-51085-x
Linares, R., Rosas, G., Vieyra, E., Chaparro, A., Espinoza, J. A., Ramírez, D. A., Silva, C., Rosas, P., Macías, V.-M., & Morales‐Ledesma, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114715 · Cited by 1
“At the neuroendocrine level, PCOS has been proposed to originate from an abnormal increase in the frequency of gonadotropin-releasing hormone (GnRH) pulses, which favors luteinizing hormone (LH) secretion over follicle-stimulating hormone (FSH) secretion [12,13].”
Menek, M. Y., Sen, M., & Pehlivan, M. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1758959 · Cited by 1
Mittal, N., Singhal, S. R., & Mittal, R. (2026) · Trials · doi:10.1186/s13063-026-09534-5
“…peptide 1 receptor agonists (GLP1RAs), dipeptidyl peptidase-4 inhibitors (DPP4i) and sodium glucose co-transporter-2 inhibitors (SGLT2i) in modifying the metabolic features of PCOS (IR, obesity and impaired glucose metabolism), regularizing menstrual cycles and inducing ovulation [16–26].”
Ji, Y., Yu, L., Dong, Y., Huo, Y., Qi, Z., Liu, Y., & Wang, F. (2026) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.70359
Hasan, B., Bash, A. A., & Hamza, L. F. (2026) · PAIN JOINTS SPINE · doi:10.1922/pjs.16.3s.2026.569
Computational Modelling in Polycystic Ovary Syndrome: A Comprehensive Review
-, P. S. K., Jawahire, M. S., Burli, S. C., Dhole, V. R., & Patil, M. A. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.55s.36
Miller, K. A. R., dos Santos, P. L., Amador, W. F. O., Servidoni, A. C. P., Martin, G. C. D. C., Reimão, D. L. P., Pinheiro, G. M., & Batzofin, J. H. (2026) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2026.105826
Baños, K. A. C., Martínez, J. J. H., Ariza‐Ortega, J. A., & Calderón‐Ramos, Z. G. (2026) · Revista Científica de Salud y Desarrollo Humano · doi:10.61368/r.s.d.h.v7i2.1071
Cardiovascular–kidney–metabolic syndrome in women: a hormonal stage–informed precision approach
Mousavi, T., Yazdanfar, F., Nikfar, S., Khorsan, R., Kamgar, M. K., Vaseghi, M., & Nobakht, N. (2026) · npj Women s Health · doi:10.1038/s44294-026-00153-8
“In addition, female-speci fi c conditions such as polycystic ovary syndrome (PCOS) 10,11 and adverse pregnancy outcomes 12,13 can result in metabolic stress earlierinlife and may contribute to later CKM risk.”
Self-citationBasnet, S., Marasine, N. R., Paudel, S., Pant, P., & Sankhi, S. (2026) · Journal of Public Health Research · doi:10.1177/22799036261465332
“7 Management of this multifactorial condition primarily emphasizes lifestyle modifications such as regular physical activity, balanced diet, and smoking cessation as first-line interventions.”
Experimental method for modeling polycystic ovary syndrome in rats: a cross-sectional study
Borozdenko, D. A., Stislavskaya, S., Pyrkova, O., & Lyakhmun, D. N. (2026) · Russian Medicine · doi:10.17816/medjrf702631
Pati, S. S., Choudhary, N. L., Kumar, U., Verma, A., Jain, S., & Kumar, A. (2026) · Current Pharmaceutical Design · doi:10.2174/0113816128467570260622104030
miR‐191‐5p Is Involved in Polycystic Ovary Syndrome by Targeting SOX4
Du, J., Yanni, A., Sun, S., Wang, J., Guo, R., Liu, L., & Zhuang, W. (2026) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70974
Wang, J., Yang, Y., Wang, Z. X., Liu, C., Han, Y., Wu, X., & Chang, H. (2026) · Frontiers in Reproductive Health · doi:10.3389/frph.2026.1901207
“External factors involve environmental pollution, life stress, and diet, while internal factors are associated with oxidative stress (OS), mitochondrial dysfunction,chronic low-grade inflammation, and metabolic disturbances that impair normal ovarian function (3).”
Ezugwu, G. I., Ezugwu, E. E., Ugwuanyi, D. C. (., Manafa, P. O., Ugwu, A. C., Olayinka, O. K., & Abonyi, I. C. (2026) · GSC Advanced Research and Reviews · doi:10.30574/gscarr.2026.28.1.0173
Morawska, M., Siwiec, A., Jakubik, M., Kiżewska, M., Szymczyk, K., Dargacz, A., Szczepańska, D., Ożga, A., Kozikowska, J., Owczarzak, M., et al. (2026) · Humanities & Social Sciences Reviews · doi:10.18510/hssr.2026.1424
Browarska, E., Mszyca, I., Miemczyk, K., Aksamit, A., Wołek, F. T., Michalski, Ł., Gajewska, N., Mularczyk, K. N., Kucharski, K., & Superson, K. (2026) · Quality in Sport · doi:10.12775/qs.2026.66.73842
Deng, X., Zhang, Y., Zeng, H., Fukui, S., & Huang, H. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s626049
“4,5 8 These interconnected pathways form a vicious cycle of metabolic abnormality-hormonal disorder-inflammation/OS, driving disease progression and exacerbating associated complications.”
Manickam, V., & Pillai, V. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1858238
Samareh, A. N., Samare‐Najaf, M., Ghafari, M., Pourghadamyari, H., Asadikaram, G., Barkam, M., & Rastegar, S. (2026) · Reproductive Sciences · doi:10.1007/s43032-026-02176-7
“Within the ovary, elevated insulin and IGF-1 levels may impair folliculogenesis and promote granulosa cell apoptosis, contributing to arrested follicular development [10, 39, 41–43].”
Zhou, J., & Sun, Y. (2026) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2026.2697493
Hunter, M., & Cirrincione, L. R. (2026) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2026.2726547
“…modifications, treatment may include metformin, combined oral contraceptives, androgen receptor antagonists (e.g. spironolactone), and 5α-reductase inhibitors (e.g. finasteride) to address androgenetic alopecia in adults, as well as non-pharmacologic interventions such as electrolysis [62].”
Vijayakumar, V., & Rathinam, T. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02618-y
“Polycystic Ovary Syndrome (PCOS) is among the most prevalent endocrine–metabolic disorders affecting women of reproductive age, with global prevalence estimates rang - ing from 8% to 13% depending on diagnostic criteria such as the Rotterdam framework [ 1 ].”
Wu, S., Shi, J., He, C., Chen, J., Guo, Q., Li, S., Tong, J., Chen, Q., Yan, Z., Du, J., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1904695
“This PC species is a major component of mammalian cell membranes, and its marked reduction is associated with decreased de novo PC synthesis or impaired hepatic transport (29, 33).”
Pan, M., Huang, J., Yan, J., Mo, J., Dong, K., Ding, Y., Zhang, G., Huang, W., Yang, Z., Wang, N., et al. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110474
Epigenetic Mechanisms Underlying Polycystic Ovary Syndrome.
Armas‐López, L. (2026) · The Journal of Reproduction · doi:10.58779/tjorvol4num1/4
Al‐Fawaeir, S. (2026) · Diseases · doi:10.3390/diseases14090341
“Around ten percent of women experience PCOS before to menopause and deal with its implications [3].”
Oktanella, Y., Husna, S. M., Putri, N. F. R., Jamilaturrosyidah, J., & Mahalita, N. R. (2026) · Advances in Animal and Veterinary Sciences · doi:10.17582/journal.aavs/2026/14.10.2180.2189
Sahu, G., & Goyal, A. K. (2026) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2026.102678
Çakmak, B. D., Özgen, G., Ertürk, N. K., Kuzey, H. C., & Gölcük, E. K. (2026) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.70502 · Cited by 1
Halder, D., Varshini, P., V, Mitra, T., Kumar, A. H. S. A., Agrawal, P., Das, M., Kumar, A. H. S. A., Kumari, R. S., Sundari, S. N. M., & Janardhanan, R. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1868855
“Accumulating evidence indicates that the syndrome involves extensive interactions among neuroendocrine, metabolic, immune, hepatic, and cardiovascular systems (Sadeghi et al., 2022).”
Majid, S. (2026) · Al-Turath Medical Journal · doi:10.63964/atmj.2026.2.3.8
Mira, E., Alaswad, R., Benzaed, S., Jaaida, N. A., Aljabo, A., & Mohammed, Z. (2026) · Libyan Medical Journal · doi:10.69667/lmj.26105
Irmak, E., & Şanlıer, N. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1928327
Liponiosomal delivery of Trigonella foenum-graecum extract: Dual modulation of PCOS
Raju, M. G., Reddy, N. V. L. S., Malkapuram, M., Rout, R. R., Archana, B., & Madhavi, L. U. (2026) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2026.100897
Chen, Z., Song, H., Deng, J.-J., Wu, Y.-X., Liu, T.-J., Xia, M., Lin, A.-L., Chen, C., Feng, J.-Y., & Yang, H. (2026) · Biology Direct · doi:10.1186/s13062-026-01011-y
Kaur, S. (2026) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-38951
Bagheri, R. B., Quchani, S. S. H., & Fathkouhi, M. R. (2025) · Crescent Journal of Medical and Biological Sciences · doi:10.34172/cjmb.2025.5040
“The exact causes of PCOS remain unclear, but it is thought to be driven by a complex interplay of environmental, genetic, and epigenetic factors (9).”
Serum alarin in relation to depression and anxiety in women with polycystic ovary syndrome
Elhamed, H. A., Fawzy, O., sayed, D., Elaziz, S. Y. A., Abdelgawad, H., & Khidr, E. G. (2026) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2026-0050
Metadata
- Authors
- Sadeghi, H. M., Adeli, I., Calina, D., Docea, A. O., Mousavi, T., Daniali, M., Nikfar, S., Tsatsakis, A., & Abdollahi, M.
- Affiliations
- Pharmaceutical Sciences Research Center (IR)
- Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
- University of Medicine and Pharmacy of Craiova (RO)
- Personalized Medicine Research Center (IR)
- University of Crete (GR)
- Corresponding author
- Abdollahi, Mohammad
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-01-06
- Volume
- 23
- Issue
- 2
- Pages
- 583
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8775814
- OpenAlex
- W4205636865
- Cited by
- 445
- References
- 106
- Citations by year
- 2026: 68 · 2025: 136 · 2024: 133 · 2023: 90 · 2022: 18
- FWCI
- 15.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- polycystic ovary syndrome, PCOS pathogenesis, drug repurposing, insulin resistance, hyperandrogenism, oxidative stress, inflammation, obesity, epigenetics, environmental toxins, stress, diet, statins, thiazolidinediones, SGLT2 inhibitors, DPP-4 inhibitors, GLP-1 receptor agonists, mucolytic agents, lifestyle modification, complementary and alternative medicine
- MeSH terms
- Female, Humans, Insulin Resistance, Polycystic Ovary Syndrome, Hyperandrogenism, Disease Management, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.